The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2022 | Challenges associated with biomarker testing for PD-L1 in NSCLC
Filiz Oezkan, MD, University Hospital Essen, Essen, Germany, discusses the challenges associated with testing for PD-L1 positivity in patients with non-small cell lung cancer (NSCLC), including whether the biopsy sample had been taken from the correct place, and what to do if the patient is PD-L1-negative. This interview took place at the IASLC 2022 World Conference on Lung Cancer congress in Vienna, Austria.
